FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897221567> ?p ?o ?g. }

• W2897221567 endingPage "7331" @default.
• W2897221567 startingPage "7323" @default.
• W2897221567 abstract "Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients Zhefeng Liu,1,* Lin Wu,2,* Jun Cao,3 Zhe Yang,4 Chengzhi Zhou,5 Liming Cao,6 Hao Wu,7 Haibo Shen,8 Meiling Jin,9 Yong Zhang,1 Xinru Mao,10 Jianxing Xiang,10 Ke Ma,10 Bing Li,11 Tengfei Zhang,10 Yi Hu1 1Department of Oncology, Chinese PLA General Hospital, Beijing, People’s Republic of China; 2Department of the Second Chest Medicine, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China; 3Department of Oncology, Hunan Cancer Hospital, Changsha, Hunan, People’s Republic of China; 4Department of Radiotherapy, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, People’s Republic of China; 5State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China; 6Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 7Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong, People’s Republic of China; 8Department of Thoracic Surgery, Ningbo No 2 Hospital, Ningbo, Zhejiang, People’s Republic of China; 9Department of Respiratory Medicine, Zhongshan Hospital Affiliated with Fudan University, Shanghai, People’s Republic of China; 10Department of Medicine, Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China; 11Department of Bioinformatics, Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China *These authors contributed equally to this work Purpose: ERBB2 exon 20 insertions (20ins) have been identified as oncogenic drivers in lung cancers. Lung cancer patients with 20ins benefit from afatinib. However, response heterogeneity was observed in patients harboring different 20ins subtypes. In this study, we interrogated clinical characteristics in ERBB2-mutated Chinese lung cancer and investigated the clinical outcomes of specific ERBB2 20ins in response to afatinib. Experimental design: In this study, we retrospectively collected genomic profiling data of 7,520 lung cancer patients sequenced using next-generation sequencing in a Clinical Laboratory Improvement Amendments-certified laboratory. We analyzed the clinical and molecular features of patients harboring ERBB2 20ins and evaluated clinical outcomes of 19 patients with clinical records after afatinib treatment. Results: ERBB2 20ins were identified in 2.27% (171/7,520) of this lung cancer cohort. It occurred with a high proportion in females with adenocarcinoma histology. ERBB2 20ins was mutually exclusive with other well-established lung cancer oncogenic driver mutations. The most frequently appearing subtype was Y772_A775dup (69.6%) and several novel insertion subtypes were also identified. The correlations of specific 20ins subtypes and survival were investigated. The presence of a glycine at position 778 in ERBB2 was suggested to be a common feature of drug sensitivity mutations. Patients harboring G778_P780dup (G778) subtype achieved longer median progression-free survival and median overall survival than other 20ins (non-G778) subtypes (median progression-free survival, 10 vs 3.3 months, P=0.32; median overall survival, 19.7 vs 7 months, P=0.16). Moreover, we presented the first clinical case of a lung squamous cell carcinoma patient harboring ERBB2 20ins who achieved partial response to afatinib. Conclusion: This study interrogated the characteristics of ERBB2 20ins in a large cohort from single ethnicity and demonstrated the response heterogeneity to afatinib among different ERBB2 20ins subtypes. Further studies in a larger cohort are needed to investigate the underlying molecular mechanisms and clinical response of different ERBB2 20ins subtypes. Keywords: ERBB2, lung cancer, afatinib, survival, heterogeneity" @default.
• W2897221567 created "2018-10-26" @default.
• W2897221567 creator A5001601148 @default.
• W2897221567 creator A5003421029 @default.
• W2897221567 creator A5022608203 @default.
• W2897221567 creator A5024796661 @default.
• W2897221567 creator A5033704922 @default.
• W2897221567 creator A5041284796 @default.
• W2897221567 creator A5042334986 @default.
• W2897221567 creator A5042991739 @default.
• W2897221567 creator A5061132120 @default.
• W2897221567 creator A5061554801 @default.
• W2897221567 creator A5064022733 @default.
• W2897221567 creator A5064222660 @default.
• W2897221567 creator A5071542662 @default.
• W2897221567 creator A5074519834 @default.
• W2897221567 creator A5081589556 @default.
• W2897221567 creator A5083581319 @default.
• W2897221567 date "2018-10-01" @default.
• W2897221567 modified "2023-10-17" @default.
• W2897221567 title "Clinical characterization of <em>ERBB2</em> exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients" @default.
• W2897221567 cites W1857925087 @default.
• W2897221567 cites W1966071998 @default.
• W2897221567 cites W1995653405 @default.
• W2897221567 cites W2017600905 @default.
• W2897221567 cites W2040935952 @default.
• W2897221567 cites W2049449785 @default.
• W2897221567 cites W2065477010 @default.
• W2897221567 cites W2089071484 @default.
• W2897221567 cites W2103441770 @default.
• W2897221567 cites W2107562400 @default.
• W2897221567 cites W2110444464 @default.
• W2897221567 cites W2112854176 @default.
• W2897221567 cites W2119180969 @default.
• W2897221567 cites W2123591186 @default.
• W2897221567 cites W2133208325 @default.
• W2897221567 cites W2133867160 @default.
• W2897221567 cites W2138851777 @default.
• W2897221567 cites W2146384083 @default.
• W2897221567 cites W2155943701 @default.
• W2897221567 cites W2159192794 @default.
• W2897221567 cites W2166199281 @default.
• W2897221567 cites W2170241131 @default.
• W2897221567 cites W2262992387 @default.
• W2897221567 cites W2318605753 @default.
• W2897221567 cites W2598622710 @default.
• W2897221567 doi "https://doi.org/10.2147/ott.s173391" @default.
• W2897221567 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6205822" @default.
• W2897221567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30425522" @default.
• W2897221567 hasPublicationYear "2018" @default.
• W2897221567 type Work @default.
• W2897221567 sameAs 2897221567 @default.
• W2897221567 citedByCount "27" @default.
• W2897221567 countsByYear W28972215672020 @default.
• W2897221567 countsByYear W28972215672021 @default.
• W2897221567 countsByYear W28972215672022 @default.
• W2897221567 countsByYear W28972215672023 @default.
• W2897221567 crossrefType "journal-article" @default.
• W2897221567 hasAuthorship W2897221567A5001601148 @default.
• W2897221567 hasAuthorship W2897221567A5003421029 @default.
• W2897221567 hasAuthorship W2897221567A5022608203 @default.
• W2897221567 hasAuthorship W2897221567A5024796661 @default.
• W2897221567 hasAuthorship W2897221567A5033704922 @default.
• W2897221567 hasAuthorship W2897221567A5041284796 @default.
• W2897221567 hasAuthorship W2897221567A5042334986 @default.
• W2897221567 hasAuthorship W2897221567A5042991739 @default.
• W2897221567 hasAuthorship W2897221567A5061132120 @default.
• W2897221567 hasAuthorship W2897221567A5061554801 @default.
• W2897221567 hasAuthorship W2897221567A5064022733 @default.
• W2897221567 hasAuthorship W2897221567A5064222660 @default.
• W2897221567 hasAuthorship W2897221567A5071542662 @default.
• W2897221567 hasAuthorship W2897221567A5074519834 @default.
• W2897221567 hasAuthorship W2897221567A5081589556 @default.
• W2897221567 hasAuthorship W2897221567A5083581319 @default.
• W2897221567 hasBestOaLocation W28972215671 @default.
• W2897221567 hasConcept C121608353 @default.
• W2897221567 hasConcept C126322002 @default.
• W2897221567 hasConcept C142724271 @default.
• W2897221567 hasConcept C166957645 @default.
• W2897221567 hasConcept C188947578 @default.
• W2897221567 hasConcept C191935318 @default.
• W2897221567 hasConcept C204787440 @default.
• W2897221567 hasConcept C205649164 @default.
• W2897221567 hasConcept C2776256026 @default.
• W2897221567 hasConcept C2777256092 @default.
• W2897221567 hasConcept C2778304055 @default.
• W2897221567 hasConcept C2779438470 @default.
• W2897221567 hasConcept C2780580887 @default.
• W2897221567 hasConcept C2780586478 @default.
• W2897221567 hasConcept C512399662 @default.
• W2897221567 hasConcept C556039675 @default.
• W2897221567 hasConcept C71924100 @default.
• W2897221567 hasConceptScore W2897221567C121608353 @default.
• W2897221567 hasConceptScore W2897221567C126322002 @default.
• W2897221567 hasConceptScore W2897221567C142724271 @default.
• W2897221567 hasConceptScore W2897221567C166957645 @default.
• W2897221567 hasConceptScore W2897221567C188947578 @default.
• W2897221567 hasConceptScore W2897221567C191935318 @default.

• next